Search
Beigene Ltd
ONCAdd to Watchlist
406.960USD
+19.710+5.09%
Close 11-06 16:00（ET）
46.04BMarket Cap
87.27P/E TTM
About Beigene Ltd Company
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd Profile
Ticker SymbolONC
Company nameBeOne Medicines AG
IPO dateMar 02, 2016
CEOOyler (John Victor)
Number of employees11000
Security typeDepository Receipt
Fiscal year-endMar 02
Addressc/o BeOne Medicines I GmbH
CityBASEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code4051
Phone41616851900
Websitehttps://beonemedicines.com/
Ticker SymbolONC
IPO dateMar 02, 2016
CEOOyler (John Victor)
Company Executives of Beigene Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
Chief Operating Officer
Chief Operating Officer
11.33K
-2.47%
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
Chief Operating Officer
Chief Operating Officer
11.33K
-2.47%
Mr. John Victor Oyler
Mr. John Victor Oyler
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Lai Wang
Dr. Lai Wang
President, Global Head of R&D
President, Global Head of R&D
--
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
Chief Operating Officer
Chief Operating Officer
11.33K
-2.47%
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
Chief Operating Officer
Chief Operating Officer
11.33K
-2.47%
Mr. John Victor Oyler
Mr. John Victor Oyler
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
FAQs
Who are the top five shareholders of Beigene Ltd?
The top five shareholders of Beigene Ltd are: Dr. Xiaobin Wu, Ph.D.
How many institutions hold shares of Beigene Ltd (ONC)?
As of 2026Q1, 602 institutions hold shares of Beigene Ltd, with a combined market value of approximately 40.42M, accounting for 36.84% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1961186.00.
What is the biggest source of revenue for Beigene Ltd?
In 2026Q1, the Product business generated the highest revenue for Beigene Ltd, amounting to 1.64B and accounting for 96.30% of total revenue.